Examining Hepatitis C Virus Treatment Access
A Review of Select State Medicaid Fee-For-Service and Managed Care Programs
Last Updated on May 13, 2020 by HepFree NYC
Related Articles
-
NYS DOH Review Viekira Pak & Preferred Status for HCV Drugs
On February 26th, the New York State Drug Utilization Review Board will meet to review and recommend NYS Medicaid clinical criteria for Viekira Pak - the most recently approved Hepatitis C therapy - marketed by AbbVie.
-
NYS DOH Drug Utilization Review Board Meeting | 4-27-16
VOCAL-NY and community leaders will attend the meeting to advocate for unrestricted access to Hepatitis C drug coverage.
-
Advancing HIV & Viral Hepatitis Testing with Point-Of-Care Diagnostics for People with Substance Use Disorder
SAMSHA and the CDC urges public health and substance use disorder (SUD) treatment communities to increase the number of people tested and treated for HIV and viral hepatitis.
-
Presidential Proclamation | World Hepatitis Day 2015
Presidential Proclamation | World Hepatitis Day 2015 As President, I am committed to advancing the fight against viral hepatitis. The Affordable Care Act has increased access to quality, affordable health care. BY THE PRESIDENT OF THE UNITED STATES OF AMERICA Around the wo...
-
Article | TB & Viral Hepatitis, New York City, 2000–2010
Literature surrounding the burden of and factors associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in persons with tuberculosis (TB) disease remains limited and focused on populations outside the USA.
-
NYS DOH Approves Viekira Pak as Preferred Drug for Hep C for FFS Medicaid Beneficiaries
YSDOH Drug Utilization Review Board meeting, the board voted to approve Viekira Pak as its preferred drug for persons chronically infected with HCV and enrolled in FFS Medicaid. Viekira Pak will be available for all chronically infected persons regardless of disease severity. Thi...
-
Clinical Preceptorship in Hep C and HIV Treatment (AETC)
This CME activity is intended to lead to improved patient care and safety based upon an assessment of gaps in knowledge, competence and performance.
-
Hepatitis A, B and C in New York City: 2020 Annual Report
The Hepatitis A, B and C in NYC: 2020 Annual Report provides the latest surveillance and programmatic data on viral hepatitis in NYC.
